Pharmaceutical Development Corporation presenting at Biofinance 2007



    OAKVILLE, ON, April 20 /CNW/ - Pharmaceutical Development Corporation
(www.pharmdevcorp.com) today announced that Diane Kalina, Co-founder and
President, will be presenting at Biofinance 2007 in Toronto. Ms. Kalina's
presentation will take place on Thursday, April 26th at 10:30 am at the
Toronto Marriott Eaton Centre.

    About Pharmaceutical Development Corporation

    Pharmaceutical Development Corporation (PDC) is a private Canadian
biopharmaceutical development company which in-licenses, develops and obtains
financing/partnerships for early stage opportunities in areas of unmet medical
need and for therapeutic areas in which PDC possesses in-house clinical
development expertise. Initially, the company is focusing on the women's
health areas of preterm labour and primary dysmenorrhea.
    PDC's lead molecule, PDC31 (formerly THG113.31) is a peptide which has
shown efficacy in vitro and in animal models of preterm labour. This peptide
is one of a family of peptides and peptidomimetics in-licensed from
Theratechnologies. PDC plans to develop an injectable formulation of PDC31 as
a treatment for acute treatment of pregnant women with preterm labour, and a
topical formulation of the same peptide for use in women with primary
dysmenorrhea.





For further information:

For further information: Diane Kalina, President, (905) 829-9770 ext
223; Patricia Griffin, Executive Vice President, (416) 698-0011

Organization Profile

PHARMACEUTICAL DEVELOPMENT CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890